skip to content
 

Professor Sir Alan Fersht FRS

Portrait of arf25

Our major research programme concerns the folding, stability and activity of proteins. We apply a broad multi-disciplinary approach that combines methods and ideas of molecular biology and physical-organic chemistry. We use techniques including protein engineering, DNA cloning, sequencing and mutagenesis, cell culture, gene and peptide synthesis, spectroscopy, rapid reaction techniques, multi-dimensional NMR (we have a 500, 600, 700 and an 800 MHz spectrometers) and x-ray protein crystallography.

Current major projects include: protein folding, misfolding and disease; drug discovery; and structure-activity relationships of proteins involved in cancer and disease.

Although now emeritus, I am still fully active in research with long term funding, including an MRC Programme Grant.

Publications

Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines
MGJ Baud, MR Bauer, L Verduci, FA Dingler, KJ Patel, D Horil Roy, AC Joerger, AR Fersht
– Eur J Med Chem
(2018)
152,
101
The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.
E Madan, TM Parker, MR Bauer, A Dhiman, CJ Pelham, M Nagane, ML Kuppusamy, M Holmes, TR Holmes, K Shaik, K Shee, S Kiparoidze, SD Smith, Y-SA Park, JJ Gomm, LJ Jones, AR Tomás, AC Cunha, K Selvendiran, LA Hansen, AR Fersht, K Hideg, R Gogna, P Kuppusamy
– J Biol Chem
(2018)
293,
4262
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
NC Synnott, MR Bauer, S Madden, A Murray, R Klinger, N O'Donovan, D O'Connor, WM Gallagher, J Crown, AR Fersht, MJ Duffy
– Cancer letters
(2018)
414,
99
Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?
NC Synnott, MR Bauer, SF Madden, AM Murray, R Klinger, N O'Donovan, D O'Connor, WM Gallagher, J Crown, AR Fersht, MJ Duffy
– JOURNAL OF CLINICAL ONCOLOGY
(2017)
35,
Structures of closed and open conformations of dimeric human ATM.
D Baretić, HK Pollard, DI Fisher, CM Johnson, B Santhanam, CM Truman, T Kouba, AR Fersht, C Phillips, RL Williams
– Sci Adv
(2017)
3,
e1700933
Multisite aggregation of p53 and implications for drug rescue
GZ Wang, AR Fersht
– Proceedings of the National Academy of Sciences of the United States of America
(2017)
114,
E2634
Multisite aggregation of p53 and implications for drug rescue
G Wang, AR Fersht
– Proceedings of the National Academy of Sciences of the United States of America
(2017)
114,
E2634
Design of a molecular support for cryo-EM structure determination.
TG Martin, TAM Bharat, AC Joerger, X-C Bai, F Praetorius, AR Fersht, H Dietz, SHW Scheres
– Proceedings of the National Academy of Sciences of the United States of America
(2016)
113,
E7456
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.
MR Bauer, AC Joerger, AR Fersht
– Proceedings of the National Academy of Sciences of the United States of America
(2016)
113,
E5271
An in silico algorithm for identifying stabilizing pockets in proteins: Test case, the Y220C mutant of the p53 tumor suppressor protein
D Bromley, MR Bauer, AR Fersht, V Daggett
– Protein Engineering Design and Selection
(2016)
29,
377
  •  
  • 1 of 64
  • >

Research Interest Group

Email address

arf25@cam.ac.uk